PlainPharmaWatch

CMS Open Payments · Program Year 2024

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. reported $1,090,100.60 in payments to 153 physicians and teaching hospitals across 230 transactions.

See the rankings → How this is sourced
$1.1M
Total payments
230
Transactions
153
Recipients
#603
of 1,925 companies

X4 Pharmaceuticals, Inc. reported $1,090,100.60 in payments to 153 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #603 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $7.1K per recipient across 5 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

X4 Pharmaceuticals, Inc. pairs above-median payment volume with a moderately concentrated payment pattern.

#603
of 1,925 companies
0.0%
of all US industry payments
0.5%
paid to its single top recipient
5
payment categories

How X4 Pharmaceuticals, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

X4 Pharmaceuticals, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$1,090,101 Top 31% higher than 69% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for X4 Pharmaceuticals, Inc.

$1,090,100.60: that is what X4 Pharmaceuticals, Inc. reported in payments to 153 physicians and teaching hospitals during Program Year 2024, spread across 230 transactions ($4.7K per transaction, $7.1K per recipient). The company sits at rank #603 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 5 general-payment categories charted below, "Royalty or License" is the largest at $40.0K across 1 transactions, 3.7% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 5 types of general payments, X4 Pharmaceuticals, Inc.'s largest category was "Royalty or License" at $40.0K - 3.7% of the company's reported total.

How X4 Pharmaceuticals, Inc. divides its payments

General-payment categories, ordered by reported total

1. Royalty or License$40.0K2. Consulting Fee$31.3K3. Food and Beverage$5.7K4. Travel and Lodging$3.8K5. Education$42.97
Payment Type Amount Transactions
Royalty or License $40.0K 1
Consulting Fee $31.3K 12
Food and Beverage $5.7K 126
Travel and Lodging $3.8K 13
Education $42.97 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $67,997.77 (84.1%) of $80,863.28 in this company's General Payments records across 128 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for X4 Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Dana-Farber Cancer Institute$40.0KNiraj Patel$12.5KAntoine Azar$5.8KNicholas Hartog$5.2KAllison Remiker$4.5K
  1. 1

    Dana-Farber Cancer Institute

    $40,000.00 across 1 reported transactions

  2. 2

    Niraj Patel

    $12,479.73 across 10 reported transactions

  3. 3

    Antoine Azar

    $5,827.50 across 2 reported transactions

  4. 4

    Nicholas Hartog

    $5,220.54 across 4 reported transactions

  5. 5

    Allison Remiker

    $4,470.00 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $4.7K. Average per recipient: $7.1K.

Total Amount

$1,090,100.60

Avg per Transaction

$4.7K

Avg per Recipient

$7.1K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

X4 Pharmaceuticals, Inc. Share

0.0%

#603 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to X4 Pharmaceuticals, Inc.

Cerapedics Inc.

$1.1M 2,115 recipients

Harrow Eye, LLC

$1.1M 11,566 recipients

CONMED Corporation

$1.1M 3,570 recipients

Kyowa Kirin Co., Ltd

$1.1M 29 recipients

Neuronetics, Inc.

$1.1M 2,122 recipients

Lumenis BE inc

$1.1M 694 recipients

Frequently Asked Questions

How much did X4 Pharmaceuticals, Inc. pay to physicians and hospitals in 2024? ▾
0.0% of all industry payments reported to CMS Open Payments for 2024 came from X4 Pharmaceuticals, Inc., totaling $1,090,100.60 across 230 transactions to physicians and hospitals.
How many physicians received payments from X4 Pharmaceuticals, Inc.? ▾
Averaging $7.1K per recipient, X4 Pharmaceuticals, Inc.'s 2024 payments reached 153 physicians and teaching hospitals.
What types of payments did X4 Pharmaceuticals, Inc. make? ▾
X4 Pharmaceuticals, Inc. made 5 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Royalty or License" at $40.0K, representing 3.7% of the company's reported total.
How does X4 Pharmaceuticals, Inc. rank among pharmaceutical companies? ▾
By total payment amount, X4 Pharmaceuticals, Inc. sits at #603 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from X4 Pharmaceuticals, Inc.? ▾
X4 Pharmaceuticals, Inc.'s 230 transactions to 153 recipients in 2024 averaged $4.7K per transaction.
Where does the payment data for X4 Pharmaceuticals, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download X4 Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.